

Sun Pharmaceutical Industries Ltd.

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
CIN: L24230GJ1993PLC019050



August 29, 2022

National Stock Exchange of India Limited

Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051,
Maharashtra, India.

BSE Limited

1st Floor, P. J. Towers,
Dalal Street, Mumbai – 400 001,
Maharashtra, India.

Scrip Symbol: SUNPHARMA

Scrip Code: 524715

Dear Sir / Madam,

Sub: Proceedings of 30th Annual General Meeting of Sun Pharmaceutical Industries Limited (“Company”) held on August 29, 2022 and intimation of Change in the Board of Directors of the Company

1. Brief Proceedings of 30th Annual General Meeting

- The 30th Annual General Meeting (“AGM”) of the Company was held today i.e. Monday, August 29, 2022 at 03:00 p.m. IST through Video Conferencing (“VC”) / Other Audio-Visual Means (“OAVM”) in compliance with the circulars issued by the Ministry of Corporate Affairs and Securities and Exchange Board India from time to time.
- Mr. Israel Makov, Chairman of the Company occupied the chair and upon confirmation of requisite quorum being present, conducted the proceedings of the AGM.
- All the Directors of the Company participated in the AGM through Video Conferencing.
- Representatives from S R B C & Co. LLP, Statutory Auditors, KJB & Co LLP, Secretarial Auditors and M/s. B.M. Sharma and Associates, Cost Auditors of the Company had participated in the AGM.
- As per requirement of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Companies Act, 2013, remote e-voting facility was made available from August 26, 2022 to August 28, 2022 to the members to cast their votes on each of the resolutions as set out in the Notice of this Meeting. The said facility was also made available to the shareholders during the AGM and for 15 minutes after the conclusion of the Meeting.
- Mr. Chintan Goswami, Partner of KJB & Co LLP, Practicing Company Secretaries, appointed as Scrutinizer to scrutinize the voting done through the remote e-voting and e-voting during the Meeting, had joined the Meeting through Video Conferencing.
- Mr. Israel Makov, Chairman of the Company, then delivered the Chairman's speech.
- The resolutions which were put up for voting at the 30th AGM are provided in **Annexure A**.
- Members who had registered themselves as speakers for the Meeting, were invited to ask questions/ queries. The questions/ queries raised were suitably replied by Mr. Dilip S. Shanghvi, Managing Director of the Company.



- The Chairman requested the Scrutinizer to complete the scrutinizing process and submit the report to Mr. Anoop Deshpande, who is authorized to submit the voting results along with Scrutinizer's Consolidated Report to the stock exchanges within 48 hours of the conclusion of the AGM.
- The voting results and the Scrutinizer's Consolidated Report shall be uploaded on the website of the Company and Central Depository Services (India) Limited (the agency appointed for providing e-voting facility) and on the notice board of the Company at its registered office and corporate office.
- All the resolutions set out in the Notice of the AGM, were approved by the equity shareholders of the Company with requisite majority.

2. Change in Board of Directors of the Company

- Mr. Israel Makov (DIN: 05299764) has retired and ceased to be the Chairman and Director of the Company upon the conclusion of Annual General Meeting held on August 29, 2022.
- Mr. Gautam Doshi (DIN: 00004612) is re-appointed as an Independent Director of the Company for a second term of 5 years, from May 25, 2023 to May 24, 2028
- Mr. Dilip Shanghvi (DIN: 00005588) is re-appointed as Managing Director of the Company for a further period of 5 years, from April 1, 2023 to March 31, 2028.

We request you to kindly take note of the same.

Thanking You,
Yours Faithfully,

For **Sun Pharmaceutical Industries Limited**

Anoop Deshpande
Company Secretary & Compliance Officer

Encl: As above



Annexure A

S. N.	Details of Resolution	Resolution Type
ORDINARY BUSINESS:		
1(a).	Adoption of Audited Standalone Financial Statements of the Company for the financial year ended March 31, 2022, and the reports of the Board of Directors and Auditors thereon.	Ordinary
1(b).	Adoption of the Audited Consolidated Financial Statements of the Company for the financial year ended March 31, 2022.	Ordinary
2.	Confirmation of Interim Dividend of Rs. 7/- per equity share, and declaration of Final Dividend of Rs. 3/- per equity share, for the financial year 2021-22.	Ordinary
3.	Re-appointment of Mr. Sailesh T. Desai, who retires by rotation, as a Director	Ordinary
4.	Re-appointment of M/s S R B C & Co LLP, Chartered Accountants as the Statutory Auditors of the Company for a further period of 5 years from the conclusion of this 30th Annual General Meeting until the conclusion of the 35th Annual General Meeting of the Company.	Ordinary
SPECIAL BUSINESS:		
5.	Retirement by rotation of Mr. Israel Makov and the vacancy created as such, is not proposed to be filled up.	Ordinary
6.	Ratification of remuneration to K D & Co, Cost Accountants, the Cost Auditors for financial year 2022-23.	Ordinary
7.	Payment of commission of Rs. 40,00,000/- each to Dr. Pawan Goenka, Mr. Gautam Doshi and Ms. Rama Bijapurkar, Independent Directors of the Company, for the financial year 2021-22.	Special
8.	Re-appointment of Mr. Gautam Doshi as an Independent Director of the Company for a second term of 5 years, from May 25, 2023 to May 24, 2028.	Special
9.	Re-appointment of Mr. Dilip Shanghvi as Managing Director of the Company and his remuneration, for a period of 5 years, from April 1, 2023 to March 31, 2028.	Special
10.	Approval of related party transactions between two non-wholly-owned subsidiaries of the Company, that is, Taro Pharmaceuticals USA, Inc. and Taro Pharmaceuticals Inc. Canada for purchase and sale of pharmaceutical products, for a period of 2 financial years, from April 1, 2022 to March 31, 2023 and April 1, 2023 to March 31, 2024, up to an aggregate value equivalent to Rs. 2,000 crores for each financial year.	Ordinary